FOXO1 and alveolar rhabdomyosarcoma: PAX3-FOXO1 is associated with a poor prognosis and a 5-year survival rate of less than 30% for ARMS patients, and once metastasis occurs, ARMS becomes resistant to conventional chemotherapy and radiotherapy.